vs
Side-by-side financial comparison of RADWARE LTD (RDWR) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RADWARE LTD is the larger business by last-quarter revenue ($75.3M vs $60.1M, roughly 1.3× RHYTHM PHARMACEUTICALS, INC.). RADWARE LTD runs the higher net margin — 7.5% vs -92.6%, a 100.1% gap on every dollar of revenue. Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 7.1%).
Radware Ltd. is an American provider of cybersecurity and application delivery products for physical, cloud and software-defined data centers. Radware's corporate headquarters are located in Mahwah, New Jersey. The company also has offices in Europe, Africa and Asia Pacific regions. The company's global headquarters is in Israel. Radware is a member of the Rad Group of companies and its shares are traded on NASDAQ.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
RDWR vs RYTM — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $75.3M | $60.1M |
| Net Profit | $5.7M | $-55.6M |
| Gross Margin | 80.7% | 88.1% |
| Operating Margin | 4.1% | -87.1% |
| Net Margin | 7.5% | -92.6% |
| Revenue YoY | — | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $60.1M | ||
| Q4 25 | — | $57.3M | ||
| Q3 25 | $75.3M | $51.3M | ||
| Q2 25 | $74.2M | $48.5M | ||
| Q1 25 | $72.1M | $32.7M | ||
| Q4 24 | — | $41.8M | ||
| Q3 24 | $69.5M | $33.3M | ||
| Q2 24 | $67.3M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | — | $-47.5M | ||
| Q3 25 | $5.7M | $-52.9M | ||
| Q2 25 | $4.2M | $-46.6M | ||
| Q1 25 | $4.3M | $-49.5M | ||
| Q4 24 | — | $-43.3M | ||
| Q3 24 | $3.1M | $-43.6M | ||
| Q2 24 | $1.7M | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | 80.7% | 89.3% | ||
| Q2 25 | 80.7% | 88.6% | ||
| Q1 25 | 80.6% | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | 80.7% | 88.5% | ||
| Q2 24 | 80.6% | 89.9% |
| Q1 26 | — | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | 4.1% | -102.6% | ||
| Q2 25 | 3.8% | -93.4% | ||
| Q1 25 | 2.2% | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | -0.0% | -132.0% | ||
| Q2 24 | -1.8% | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | — | -83.0% | ||
| Q3 25 | 7.5% | -103.1% | ||
| Q2 25 | 5.7% | -96.1% | ||
| Q1 25 | 6.0% | -151.4% | ||
| Q4 24 | — | -103.6% | ||
| Q3 24 | 4.5% | -131.2% | ||
| Q2 24 | 2.5% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | — | $-0.75 | ||
| Q1 25 | — | $-0.81 | ||
| Q4 24 | — | $-0.71 | ||
| Q3 24 | — | $-0.73 | ||
| Q2 24 | — | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.7M | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $357.1M | $122.9M |
| Total Assets | $618.7M | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | — | $388.9M | ||
| Q3 25 | $98.7M | $416.1M | ||
| Q2 25 | $98.7M | $291.0M | ||
| Q1 25 | $98.7M | $314.5M | ||
| Q4 24 | — | $320.6M | ||
| Q3 24 | $70.5M | $298.4M | ||
| Q2 24 | $70.5M | $319.1M |
| Q1 26 | — | $122.9M | ||
| Q4 25 | — | $139.1M | ||
| Q3 25 | $357.1M | $148.8M | ||
| Q2 25 | $357.1M | $-11.9M | ||
| Q1 25 | $357.1M | $18.9M | ||
| Q4 24 | — | $21.7M | ||
| Q3 24 | $323.3M | $11.2M | ||
| Q2 24 | $323.3M | $39.3M |
| Q1 26 | — | $442.3M | ||
| Q4 25 | — | $480.2M | ||
| Q3 25 | $618.7M | $506.9M | ||
| Q2 25 | $618.7M | $372.7M | ||
| Q1 25 | $618.7M | $386.7M | ||
| Q4 24 | — | $392.3M | ||
| Q3 24 | $571.9M | $363.6M | ||
| Q2 24 | $571.9M | $381.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
